Skip to main content
SpringerLink
Log in

Myeloablative autologe Stammzelltransplantation zur Behandlung der schweren Systemsklerose

Autologous stem cell transplantation with a myeloablative regimen for treatment of severe systemic sclerosis

  • Klinische Studien kurzgefasst
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498–506

    Article  CAS  PubMed  Google Scholar 

  2. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498

    Article  PubMed  Google Scholar 

  3. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Interdisziplinäre Rheumatologie, klinische Immunologie und Autoimmunerkrankungen (INDIRA) und Innere Medizin II (Onkologie, Hämatologie, Rheumatologie, Immunologie und Pulmologie), Universitätsklinik Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland

    J. C. Henes

Authors
  1. J. C. Henes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. C. Henes.

Ethics declarations

Interessenkonflikt

J.C. Henes weist auf folgende Beziehungen hin: nichtzweckgebundene Forschungszuwendung von Fresenius, nun NEOVII Biotech GmbH.

Additional information

Redaktion

C. Fiehn, Baden Baden

B. Hellmich, Kirchheim-Teck

I. Kötter, Hamburg

K. Krüger, München

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henes, J.C. Myeloablative autologe Stammzelltransplantation zur Behandlung der schweren Systemsklerose. Z Rheumatol 77, 343–344 (2018). https://doi.org/10.1007/s00393-018-0448-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-018-0448-z

Search

Navigation